Clinical Edge Journal Scan

Meta-analysis demonstrates better survival outcomes with breast-conserving surgery vs mastectomy


 

Key clinical point: Women with early-stage invasive breast cancer (BC) who underwent breast-conserving surgery with radiotherapy (BCS) had better overall survival (OS) than those who underwent mastectomy.

Major finding: Compared with mastectomy, BCS was associated with improved OS in the overall population of patients with early-stage invasive BC (relative risk [RR] 0.64; 95% CI 0.55-0.74), with stronger effects observed in women followed-up for <10 years (RR 0.54; 95% CI 0.46-0.64).

Study details : Findings are from a meta-analysis of 30 studies including 1,802,128 women with early-stage invasive BC, of which 1,075,563 and 744,565 patients underwent BCS and mastectomy, respectively, and were followed-up for 4-20 years.

Disclosures: This study did not receive any external funding. Dr. Chatterjee declared serving as a consultant for 3M and Royal.

Source: De la Cruz Ku G et al. Does breast-conserving surgery with radiotherapy have a better survival than mastectomy? A meta-analysis of more than 1,500,000 patients. Ann Surg Oncol. 2022 (Jul 25). Doi: 10.1245/s10434-022-12133-8

Recommended Reading

Lung adverse effects in patients taking trastuzumab deruxtecan
MDedge Hematology and Oncology
Pembrolizumab+chemotherapy improves OS in a subgroup of patients with advanced TNBC
MDedge Hematology and Oncology
Bed boost after WBI reduces local recurrence of ductal carcinoma in situ in the breast
MDedge Hematology and Oncology
TNBC: First-line nab-paclitaxel+cisplatin effective and safe in phase 3
MDedge Hematology and Oncology
ERBB2-positive BC: Adding atezolizumab to PATH shows acceptable pCR rate in phase 2
MDedge Hematology and Oncology
Oral paclitaxel+encequidar offers a possible alternative to IV paclitaxel in metastatic BC
MDedge Hematology and Oncology
ER+ HER2− early BC: Patients with PEPI 0-1/pCR can safely skip adjuvant chemotherapy
MDedge Hematology and Oncology
Early-stage ER+ BC: No recurrence or mortality with systemic or vaginal hormone therapy
MDedge Hematology and Oncology
ER+ BC: Long-term benefits of endocrine therapy in premenopausal women
MDedge Hematology and Oncology
Childbirth does not impact survival in women with previously treated BC
MDedge Hematology and Oncology